Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Accounts Payables (2016 - 2025)

Apyx Medical (APYX) has disclosed Accounts Payables for 16 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 16.94% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, up 16.94%, and an annual FY2025 reading of $3.1 million, up 16.94% over the prior year.
  • Accounts Payables was $3.1 million for Q4 2025 at Apyx Medical, down from $3.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $3.2 million in Q3 2025 and bottomed at $1.9 million in Q1 2023.
  • Average Accounts Payables over 5 years is $2.5 million, with a median of $2.6 million recorded in 2022.
  • The sharpest move saw Accounts Payables surged 74.12% in 2021, then tumbled 32.0% in 2022.
  • Year by year, Accounts Payables stood at $2.6 million in 2021, then increased by 1.44% to $2.7 million in 2022, then increased by 1.61% to $2.7 million in 2023, then dropped by 3.58% to $2.6 million in 2024, then grew by 16.94% to $3.1 million in 2025.
  • Business Quant data shows Accounts Payables for APYX at $3.1 million in Q4 2025, $3.2 million in Q3 2025, and $2.9 million in Q2 2025.